Hepatitis C virus core antigen (HCVcAg) testing accurately identifies acute or recent HCV infection in patients with HIV, according to study findings published in Open Forum Infectious Diseases.
Given delayed antibody responses in individuals with…

Hepatitis C virus core antigen (HCVcAg) testing accurately identifies acute or recent HCV infection in patients with HIV, according to study findings published in Open Forum Infectious Diseases.
Given delayed antibody responses in individuals with…

Yasmin RufoMagazine London
Getty ImagesA transport enthusiast, a beauty advocate and a mum teaching people how to raise an autistic child were among the winners of the second annual…

GRAIL (GRAL) just posted its third-quarter earnings, highlighting a jump in Galleri test volume and revenue. The announcement also included a partnership with Samsung, aimed at expanding into key Asian markets.
See our latest analysis for GRAIL.
After a string of upbeat quarterly results, partnerships, and a major capital infusion, GRAIL’s momentum has translated directly into the stock’s performance with a remarkable 156.6% share price return over the past 90 days and a 426.3% total shareholder return over the last year. Both recent and longer-term moves suggest investor optimism is building as commercial traction and validation grow.
If you’re curious what other companies are capturing investors’ attention in healthcare, consider discovering See the full list for free.
The recent rally has left many investors wondering: is GRAIL still undervalued given its growth trajectory, or has the current share price already baked in all the future gains?
GRAIL’s most widely followed fair value estimate stands at $61.50, which is significantly below the last close of $83.20. This notable gap highlights diverging expectations and sets up a pivotal discussion around growth, valuation, and future profitability.
Ongoing positive clinical trial results, including substantially higher cancer detection and positive predictive value with consistent specificity for Galleri in population-scale studies, are setting the stage for robust FDA approval and broad payer reimbursement, which could unlock significant new revenue streams and accelerate top-line growth.
Read the complete narrative.
What big bets are hiding inside this valuation call? The fair value hangs on ambitious revenue forecasts, eye-catching profit margin shifts, and hope of regulatory green lights. Curious just how bold the assumptions are? Find out what’s driving this price and whether the market has run ahead of the numbers.
Result: Fair Value of $61.50 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, persistent high losses and dependence on regulatory milestones remain key risks. These factors could quickly dampen optimism if progress falters.
Find out about the key risks to this GRAIL narrative.
If you see the story differently or want to do some digging on your own, you can put together your own take in under three minutes. Do it your way
A great starting point for your GRAIL research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.

Newswise — The stereotypical image of psychotherapy shows a patient lying on a couch, exploring their deepest traumas. This leads to awareness of unconscious habits, thoughts, and drives and has long been a…

(Bloomberg) — Stocks extended losses as uncertainty over Federal Reserve interest-rate cuts and stretched technology valuations weighed on sentiment, prompting investors to retreat from riskier corners of the market.
Asian shares fell 1.2% — with technology companies such as SK Hynix Inc. leading the losses — following the retreat in Wall Street benchmarks Thursday. Even so, MSCI’s gauge of global stocks is set for a fourth gain in five weeks. Bitcoin traded below $100,000 and is down more than 20% since early October. Oil jumped as traders weighed risks to Russian flows from US sanctions, which countered a slew of signs that the market faces a glut.
Treasuries and a gauge of the dollar steadied as investors parsed commentary from Fed officials that cast doubt over a December rate cut. Also, the October jobs report will be released without a reading of the unemployment rate.
Attention was also on the pound Friday, which fell after the Financial Times said UK Chancellor Rachel Reeves was ditching a planned income tax rise.
The moves dealt a fresh blow to risk sentiment, highlighted by heavy selling in high-flying tech giants amid mounting valuation concerns. Beneath the surface, some investors pointed to a rotation into more defensive sectors. With optimism over the US government’s reopening largely priced in, traders are now focusing on the upcoming wave of economic data, as the chances of a December Fed rate cut slip below 50%.
“Markets appear to be spooked to a large extent by AI froth fears,” said Vishnu Varathan, head of macro research for Asia ex-Japan at Mizuho Bank. “A Fed that is more likely to bide its time than race against it, makes it a lot less conducive for the tech rout, which typically tends to be more sensitive to Fed easing.”
Technology stocks have been under pressure recently as investors balanced optimism over technological advances with concerns over stretched artificial intelligence valuations. Wall Street chief executives have also adopted a more cautious tone recently, as the market’s gains since April’s slump have become increasingly concentrated in a handful of stocks, prompting some investors to warn of “froth” in the AI sector.
With President Donald Trump signing the legislation to end the longest shutdown in US history, investor attention is now turning to the slew of economic data that’s due to flow out. Even so, the October jobs report will skip the unemployment rate as the household survey wasn’t conducted, US top economic adviser Kevin Hassett told Fox News.
Some traders are also concerned that the omission of key may bolster arguments for Fed officials to stand pat. Currently, traders are pricing in about an even chance that the Fed will hold or cut rates in December.
Chair Jerome Powell said last month that a reduction is “not a foregone conclusion,” with the decision to be premised on incoming information.
In separate statements, Fed Bank of St. Louis President Alberto Musalem said officials should move cautiously on rates with inflation running above target, while Cleveland counterpart Beth Hammack noted policy should remain “somewhat restrictive.” Minneapolis Fed President Neel Kashkari said he didn’t support the last cut and is undecided about December.
Elsewhere, Trump is readying substantial tariff cuts designed to address high food prices and a series of new trade deals as he seeks to address voter concerns over the cost of goods.
Corporate News:
Verizon Communications Inc. is discussing plans to announce job cuts next week that could downsize the company by as much as 20%. A wave of voluntary and early retirement programs in Japan is on track to hit a four-year high, as companies from Panasonic Holdings Corp. to Japan Display Inc. try to balance an aging workforce with the need to boost competitiveness. Japan Airlines Co. has sought proposals from manufacturers for up to 70 regional and turboprop aircraft. Tencent Holdings Ltd. posted a faster-than-anticipated 15% rise in revenue. Separately, it struck a deal with Apple Inc. that will see the iPhone maker handle payments and take a 15% cut of purchases in WeChat mini games and apps, resolving a high-profile dispute. Kioxia Holdings Corp. shares were set to fall by their daily limit after the NAND memory maker’s current-quarter outlook missed expectations elevated by bullish comments from bigger rivals. Singapore Air shares fell after the carrier’s second-quarter net income slumped 82%. Some of the main moves in markets:
Stocks
S&P 500 futures rose 0.1% as of 10:55 a.m. Tokyo time Japan’s Topix fell 0.8% Australia’s S&P/ASX 200 fell 1.4% Hong Kong’s Hang Seng fell 1.1% The Shanghai Composite fell 0.1% Euro Stoxx 50 futures fell 0.3% Currencies
The Bloomberg Dollar Spot Index was little changed The euro was little changed at $1.1635 The Japanese yen was little changed at 154.47 per dollar The offshore yuan was little changed at 7.0926 per dollar Cryptocurrencies
Bitcoin rose 0.4% to $99,194.18 Ether rose 0.8% to $3,204 Bonds
The yield on 10-year Treasuries was little changed at 4.12% Japan’s 10-year yield was little changed at 1.695% Australia’s 10-year yield advanced three basis points to 4.45% Commodities
West Texas Intermediate crude rose 3.2% to $60.58 a barrel Spot gold rose 0.5% to $4,192.97 an ounce This story was produced with the assistance of Bloomberg Automation.
–With assistance from Winnie Hsu and Richard Henderson.
©2025 Bloomberg L.P.

A nationwide Japanese cohort finds no evidence that cesarean delivery increases early-life risks of eczema, wheezing, asthma, or atopic dermatitis, challenging concerns that birth mode alone drives infant allergic disease.
Study:

November 14, 2025 06:34 AM IST
First published on: Nov 14, 2025 at 06:34 AM IST
Imagine this: People, young and old, working and retired, spending hours and days…

Improved discipline and awareness of England’s strengths have occupied the All Blacks’ minds in their preparation for Sunday’s (NZT) at Twickenham.
LIVE on Sky Sport – Sunday 16 November: All Blacks vs England, 4:10AM…

Always looking to break movie marketing rules, Disney decided to drop two summer 2026 trailers yesterday – 20th Century Studios’ Devil Wears Prada 2 and Pixar’s Toy Story 5 — each posting massive reaches in their first 24 hours.
Continue Reading